Sponsored by

Poster Number Index
Click on one of the following number ranges below to display a list of posters.
Click the checkbox next to each item to bookmark.

101 – 200 | 201 – 300 | 301 – 400 | 401 – 500 | 501 – 600 | 601 – 700 | 701 – 800
801 – 900 | 901 – 1000 | 1001 – 1100 | 1101 – 1200 | 2001 – 2100 | 2101 – 2200 | 3001 – 3100
3101 – 3200 | 4001 – 4100 | 4101 – 4200 | 5001 – 5100 | 5101 – 5200 | 6001 – 6100 | 6101 – 6152

  [5001] First clinical experience of contrast enhanced digital mammography (CEDM) for the detection of breast carcinomas.
  [5002] Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer.
  [5003] Association of estrogen receptor gene alpha polymorphisms with postmenopausal mammary density.
  [5004] Intensive breast cancer screening programs including MRI influence prognosis and treatment of breast cancer among BRCA 1/2 gene mutation carriers.
  [5005] Method of detection is a prognostic factor for outcome among women diagnosed with early stage breast cancer.
  [5006] A potential serum panel for breast cancer diagnosis: ongoing clinical validation for its clinical implication.
  [5007] Bone scintigraphy (BS) may no longer be relevant in the era of integrated PET/CT for women undergoing evaluation for suspected metastatic breast cancer (MBC).
  [5008] A novel breast tissue feature strongly associated with risk of breast cancer.
  [5009] Lobular neoplasia on core biopsy and risk factors to predict upstaging at surgical excision.
  [5011] Is the incidence of breast cancer among Asian women living in the UK, higher at a younger age than that of the Caucasian women?
  [5013] Development of a blood based breast cancer test for Indian population
  [5014] The value of mammography vs. physical examination in detecting a recurrent breast cancer in women with a previous diagnosis of breast cancer.
  [5016] Improving community access for breast cancer screening.
  [5017] Association of serum tumor-related methylated DNA with circulating tumor cells in peripheral blood of breast cancer patients.
  [5018] Characterization of the HER2 status on circulating breast cancer cells.
  [5019] Minimal residual disease detection in peripheral blood of primary breast cancer patients – translational research in the SUCCESS-study.
  [5020] HER-2 expression on circulating tumor cells in metastatic breast cancer.
  [5021] Multicenter study on the detection of disseminated tumor cells in primary breast cancer.
  [5022] Monitoring cytokeratin19 (KRT19) levels as response of circulating tumor cells (CTC) to neoadjuvant chemotherapy (NAC) in breast cancer (BC).
  [5023] HER2+ circulating tumor cells (CTCs): a more sensitive and specific marker for CTCs positivity than total CTCs count in early breast cancer.
  [5024] Practical use of circulating tumor cells for the management of subsets of metastatic breast cancer patients in a community oncology practice.
  [5025] Circulating tumour cell (CTC) detection: a direct comparison between the CellSearch system, the AdnaTest, CK19/MAM RT-PCR and unmethylated/methylated free DNA in patients with metastatic breast cancer.
  [5026] Isolation of circulating tumour cells in patients with metastatic breast cancer by filter technology.
  [5027] Serial measurements of circulating tumor cells by quantitative RT-PCR in metastatic breast cancer patients receiving systemic therapy.
  [5028] Circulating tumor cells in operable breast cancer: a pilot study.
  [5029] Tumor cell quantification and normalized multi-gene expression analysis of micrometastatic cells in blood and bone marrow of cancer patients: introduction of the embedded tumor cell calibrator technique.
  [5030] Behaviour and metastatic potential of her2/neu positive and her2/neu negative circulating epithelial tumor cells (CETC) during adjuvant systemic therapy in breast cancer.
  [5031] Metastatic potential of Her2/neu positive and Her2/neu negative circulating epithelial tumor cells (CETC) released during primary systemic chemotherapy.
  [5034] Induction of cell cycle arrest and apoptosis in breast cancer cells by troglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligand.
  [5035] Obesogenic and leptogenic nutrient sensing pathways of p27Kip1: implication in breast cancer.
  [5037] Amplication of the estrogen receptor 1 (ESR1) gene in mastopathy predicts development of breast cancer.
  [5038] Role of lobular involution in pregnancy-associated breast cancer.
  [5039] Abundance and distribution of polychlorinated biphenyls (PCBs) in breast tissue.
  [5040] Is metabolic syndrome the link between obesity and postmenopausal breast cancer?
  [5041] Promoter hypermethylation is an early event in breast carcinogenesis.
  [5042] GSTP1 promoter hypermethylation during breast cancer development.
  [5043] A low number of tumor infiltrating FOXP3-positive cells after primary systemic chemotherapy is correlated with favorable relapse-free survival in breast cancer patients.
  [5044] Immune cells from pleural fluids of patients with inflammatory breast cancer are immunocompetent.
  [5045] Investigation of immuno-regulatory mechanisms relating to poor surgical wound healing and breast cancer recurrence.
  [5047] The expression of activating natural killer cell receptors in patients with primary breast cancer.
  [5051] A new paradigm for African American breast cancer involving stem cell differentiation.
  [5052] Lapatinib selectively inhibits HER2 over-expressing breast cancer stem-like cells.
  [5053] Detection of tumor stem cells among circulating epithelial tumor cells (CETC) and relationship to therapy response.
  [5055] Low proteasome activity as a means to track and target breast cancer stem cells in-vivo.
  [5057] ALDH1 expression in human breast carcinoma.
  [5058] Do stem cell markers have significant implication in breast cancer? Immunohistochemical study for CD44 and CD24.
  [5060] Exploratory study of clonality determined by expression of tumor markers in intrinsic subtypes of breast cancers.
  [5062] Differential transcriptional response to cisplatinum in BRCA1-defective versus BRCA1-reconstituted breast cancer cells by microarrays.
  [5063] Building prognostic and predictive models for cancer patients using expression modules and clinical variables.
  [5065] Hyperoxic respiratory challenges to monitor chemotherapy effects on Brca1/p53 deficient mice breast tumors.
  [5068] GATA3, P53, Ki67 and vascular peritumoral invasion are strongly predictive of hormonal resistance in luminal breast cancer.
  [5069] Genomic score predictive of metastatic evolution in breast cancer.
  [5070] αB-crystallin, vimentin and increased p53 expression levels in breast cancer is associated with poor prognosis.
  [5071] Prognostic impact of tumor-specific HMG-CoA reductase expression in primary breast cancer.
  [5072] Antibody microarray analysis identifies biomarkers associated with radioresistant breast cancer cell lines.
  [5073] Sirtuin expression is decreased in malignant breast tissue and is associated with patient outcome.
  [5074] Quantitative proteomic analysis of radioresistant breast cancer cell lines.
  [5075] JNK, essential for anticancer therapy-induced apoptosis, promotes breast cancer progression.
  [5076] Oxytocin administration, but not social housing condition, reduces growth rate of human breast cancer xenografts (MCF7) in SCID mice.
  [5077] Facilitators and barriers to recruitment for an exercise and dietary intervention study in minority breast cancer survivors.
  [5078] Breast cancer fear in girls: a major “side effect” of breast cancer in loved ones and a backlash of ubiquitous media coverage.
  [5079] Levels of 25-hydroxy-vitamin D in pre-menopausal women at high risk for development of breast cancer.
  [5080] Comparison of weight loss with a National Cancer Institute diet and a plant-based olive oil diet in overweight women with invasive breast cancer.
  [5081] Enterolactone but not genistein decreases estradiol-induced tumor growth, angiogenesis, and secreted VEGF in vivo in human breast cancer.
  [5082] Regulation of adipocyte lipid homeostasis by genistein alters mammary epithelial cell differentiation: a paracrine mechanism for mammary tumor protection.
  [5084] Evidence that SOM230 can prevent experimental mammary hyperplasia by blocking IGF-I and thus estrogen action in the mammary gland: preliminary evidence for an effect in humans.
  [5085] Characteristics of carpal-tunnel syndrome in the ATAC trial.
  [5086] Effect of exemestane on bone mineral density in postmenopausal women at increased risk for breast cancer.
  [5089] Use of mastectomy in rural versus urban patients: the effects of medical community factors.
  [5090] Day surgery for breast cancer: a pilot randomised controlled trial.
  [5091] Choosing chemotherapy: who says “yes please”?
  [5092] Adherence to mammographic screening in a centralized breast health program in South Brazil: preliminary results.
  [5093] Hormone therapy – who takes it – the rich or the poor?
  [5094] Choosing breast reconstruction – for richer, for poorer?
  [5096] Influence of private practice setting on adjuvant chemotherapy use for elderly women with early-stage breast cancer.
  [5098] Patient perception of choice in decision-making for early-stage breast cancer: do race and socioeconomic status matter?
  [5099] Racial disparities in breast cancer knowledge.
  [5100] Racial disparities in magazine coverage of mammography.

 
 

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved